马德里格尔制药

US · MDGL #1355 按市值排名上市于 2016

449.74 -10.07 -2.19%

实时 - 追踪5344个代码 - 心跳于505秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了1家。
机构持股总比例下降了0.3个百分点。

机构持股

机构持股比例: 106.82% -0.33pp
机构数量: 500 +1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund54.62%

Hedge Fund41.38%

Private Company6.07%

Individual/Insider5.25%

Public Company2.58%

Government Pension Fund0.98%

Sovereign Wealth Fund0.94%

Insurance Company0.14%

主要股东截至 2026-06-30

Baker Bros. Advisors LP 9.28% · 2.14M 股

RTW Investments, LP 8.63% · 1.99M 股

Janus Henderson Group plc 8.38% · 1.94M 股

Avoro Capital Advisors LLC 7.94% · 1.83M 股

Paulson & Co. Inc. 5.80% · 1.34M 股

BlackRock 5.20% · 1.20M 股

Vanguard Capital Management, LLC 4.14% · 957.25K 股

Wellington Management Group 3.57% · 825.71K 股

Vanguard Portfolio Management, LLC 3.38% · 781.73K 股

SQN, LLC 2.84% · 655.54K 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 29次买入 · 21次卖出

姓名	职务	持股比例
Rebecca Taub	Founder, Chief Medical Officer, President of Research & Development and Director	1.91%
Frederick Craves	Lead Independent Director	1.59%
Paul Friedman	Director	0.74%
William Sibold	Chief Executive Officer	0.67%
Brian Lynch	General Counsel	0.11%
Richard Levy	Independent Director	0.10%
David Soergel	Chief Medical Officer	0.04%
Robert Waltermire	Chief Pharmaceutical Development Officer	0.03%
Raymond Cheong	Director	0.02%
Julian Baker	Independent Chairperson	0.02%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-27	Paul Friedman	Director	Intent to Sell (Form 144)	-50,000	$516.56
2026-09-10	William Sibold	Chief Executive Officer	Automatic Disposition	-5,221	$533.09–546.38
2026-09-08	William Sibold	Chief Executive Officer	Open Market Disposition	-6,362	$527.88–542.55
2026-08-16	Shannon Kelley	Chief Compliance Officer	Open Market Disposition	-664	$514.97
2026-08-14	John Reed	Director	Other Acquisition	+647	--
2026-08-14	John Reed	Director	Other Derivative Acquisition	+1,078	$507.56
2026-07-19	William Sibold	Chief Executive Officer	Derivative Exercise and Sale	-2,500	$542.75–555.05
2026-07-16	William Sibold	Chief Executive Officer	Derivative Exercise and Retained	+47,500	--
2026-06-16	Julian Baker	Independent Chairperson	Other Acquisition	+454	--
2026-06-16	Julian Baker	Independent Chairperson	Other Derivative Acquisition	+766	$499.86
2026-06-16	Jacqualyn Fouse	Director	Other Acquisition	+454	--
2026-06-16	Jacqualyn Fouse	Director	Other Derivative Acquisition	+766	$499.86
2026-06-16	Richard Levy	Independent Director	Other Acquisition	+454	--
2026-06-16	Richard Levy	Independent Director	Other Derivative Acquisition	+766	$499.86
2026-06-16	Rebecca Taub	Founder, Chief Medical Officer, President of Research & Development and Director	Other Acquisition	+454	--
2026-06-16	Rebecca Taub	Founder, Chief Medical Officer, President of Research & Development and Director	Other Derivative Acquisition	+766	$499.86
2026-06-16	James Daly	Independent Director	Other Acquisition	+454	--
2026-06-16	James Daly	Independent Director	Other Derivative Acquisition	+766	$499.86
2026-06-16	Daniel Brennan	Director	Other Acquisition	+404	--
2026-06-16	Daniel Brennan	Director	Other Derivative Acquisition	+681	$499.86

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。